Poster Session Info - October 7th

Poster board dimensions:

4 feet high by 6 feet wide

The boards are equipped with Velcro and pushpins.

Poster #	Submitter	Title
2	Lola Zerbib	Activating variants in RIT1 cause central conducting lymphatic anomaly
4	Yan Ma	The role of RAS GTPase proteostasis in PDAC
8	Ronald Hill	Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma
14	Esther Castellano	Tumor-intrinsic KRAS variants differentially instruct fibroblast and extracellular matrix states in lung adenocarcinoma - WITHDRAWN
18	Priya Hibshman	Oncogenic KRAS mutations drive estrogen independence and induce targetable vulnerabilities in treatment-resistant ER+ breast cancer
20	Natalia Ignatenko	Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells
22	Alec Berman	Initial Findings of the NIH Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) Observational Study.
24	Madison Tia Chappel	Systematic quantitation of Ras activity using NMR
26	Maria Al Haddad	Insights into Phosphoinositide 3-kinase α Cancer-Associated RAS Binding Domain Mutations: Activation and RAS Isoform Interactions
32	Luca Mazzarella	GAP, MAP or both? NF1 regulates microtubular repair through its RAS-GAP domain
34	Betty Chu	Engineering RASProteases for substrate-selective active RAS cleavage and inhibition of KRAS signaling
36	Haley Francis-Todd	MRAS reduces sensitivity to KRAS inhibition and facilitates ERK and PI3K signaling rebound in pancreatic cancer
40	Mark Philips	KRAS4A Directly Regulates Methionine Synthase Establishing a Rationale for Combination Therapy with KRAS Inhibitors and Antifolates
42	Peter Johnson	TOLLIP organizes an isoform-selective perinuclear signaling program in KRAS- and NRAS-mutant cancers
48	Jennifer Mehalko	Investigation of Neurofibromin 1 protein activation using different expression systems
50	Matthias Drosten	ETV4 and ETV5 direct a Capicua-controlled transcriptional program driving sotorasib resistance in KRAS-mutant lung adenocarcinoma
52	Jacob Neumann	Survivin Promotes the Formation of a Microtubule-Based Glycolytic Hub
54	Robert Beal	Non-canonical BRAF mutations impact leukemogenesis and cellular response to therapy in AML
60	Jinmin Zhang	Understanding USP13 as a Therapeutic Vulnerability in Cell-of-Origin-defined, KRAS-driven Lung Cancer
64	Lucille Ferret	Overcoming resistance to KRAS inhibition in co-mutated KRAS/PIK3CA colon cancer
66	Patrick Pfaff	Dual catalytic targeting of K-Ras via synergistic coupling of GAP-mimetic hydrolysis and PROTAC-mediated degradation
70	Hasmik Avagyan	Revealing Mutation-Specific Oncogenic RAS Clustering Patterns on Plasma Membrane using Nanobar Arrays
76	Grace Scheidemantle	Utilizing Parallel Reaction Monitoring (PRM) Analysis to Identify and Quantify Phosphorylation Sites of BRAF and MEK Proteins
78	Picabo Binette	Functional pleiotropy and allelic hierarchy of allele-specific tri-complex RAS-ON inhibitors
80	Victoria Bowcut	Exploiting the Unique Switch II Pocket Ligandability of the Pathogenic Rac1 Alternative Splice Variant Rac1b
82	Leonard Ash	The impacts of KRAS alleles on resistance to daraxonrasib
84	Brandon Mouery	VS-7375, a non-covalent dual ON/OFF KRAS G12D inhibitor, displays superior activity relative to ON-only RAS inhibitors in preclinical models of pancreatic cancer
86	Mumina Sadullozoda	Harnessing lipid metabolism to treat drug tolerant persister cells
88	Ryan Mouery	Strong durable tumor regressions with the KRASG12D ON/OFF inhibitor VS-7375 in combination with PRMT5 inhibition in MTAP-deleted/KRASG12D-mutant pancreatic cancer
90	Shuodan Zhang	Safety and feasibility of pre-radiation RAF-MEK and FAK/Pyk2 inhibition in newly diagnosed Glioblastoma: rationale and design of a pre-radiation multicenter trial
92	Ayodele Omotoso	Recurrent HRAS G12V Hotspot Candidates Define a RAS-Altered Subset of Nigerian High-Grade Serous Ovarian Cancer
94	Joanne Tobacman	Regulation of RAS-GTPase Activity by Oncofetal Chondroitin Sulfate (Chondroitin 4-Sulfate) and Arylsulfatase B
96	Jean Castillo	Optically induced KRAS nanoclustering engages RAC1 crosstalk to drive ERK activation.
98	Brajendra Tripathi	Mechanism-Based Targeting of Mutant KRAS-Driven Pancreatic Cancer
100	Joseph LaMorte	KEAP1/STK11 Co-mutations Program Broad Resistance to Mechanistically Diverse KRAS Inhibitors While Exposing Exploitable Metabolic and Genomic Vulnerabilities in Persister Cells
102	Isabela Fuentes	EGFR signaling in KRAS-mutant lung adenocarcinoma
106	Sara Hook	Building High-Performing R&D Cultures and Empowering the Next Generation of Scientific Leaders
108	Jessie Villanueva	Targeting S6K2 Eliminates RAS Inhibitor–Tolerant Persister Cells and Overcomes Resistance in NRAS-mutant melanoma
110	Hyun Lee	HRAS promotes mutant NRAS–driven transformation with codon and allele specificity
112	Rony Francois	LKB1 signaling opposes SHOC2-mediated RAF activation and inhibits MAPK signaling
114	Rony Francois	STK11 promotes a regulatory RAF protein-protein interaction, which is disrupted by active RAS
116	Justin Bromell	Kinase Activated Relays (KARs) to Target RAS-Driven Cancers
118	Bamidele Towolawi	Targeting the SHOC2–MRAS Complex with GNG2-Derived Variants Suppresses MAPK Signaling
120	Marielle Yohe	Impaired effector engagement and endosomal mislocalization underlie pathogenicity of the atypical Costello syndrome-associated HRAS variant S89C